04.26.18

ARVO 2018: Genentech Ophthalmology Data Highlights

Source: Genentech

Genentech will be presenting several studies at the Association for Research in Vision and Ophthalmology (ARVO) meeting on April 29 – May 3 in Honolulu. Data being reported at ARVO continue to show the safety and efficacy of Lucentis (ranibizumab) as a treatment for wet age-related macular degeneration (AMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME) and diabetic retinopathy (DR).

  • “Quarterly Anti-VEGF Dosing For The Treatment Of Neovascular Age-Related Macular Degeneration: A Cross Trial Comparison” – Presented by David Eichenbaum, M.D., Poster A0156

Sunday, April 29, 3:15pm – 5:00pm HST; Poster Session: AMD & Anti-VEGF I; Exhibit Hall

o   This retrospective analysis evaluated vision gains and stability achieved by patients receiving quarterly, rather than monthly, anti-VEGF dosing for the treatment of wet AMD across several clinical trials (CABERNET, EXCITE, VIEW, PIER, HAWK and HARRIER).

o   The results suggested that about half of patients with wet AMD respond well to a 12-week dosing interval, providing further support for the efficacy of less-than-monthly ranibizumab treatment.

  • “Association Between Timing of Peak Vision Gain and Long-Term Outcomes of Ranibizumab for nAMD: A Post Hoc Analysis of HARBOR” – Presented by Louis Chang, M.D., Ph.D., Poster A0168

Sunday, April 29, 3:15pm – 5:00pm HST; Poster Session: AMD & Anti-VEGF I; Exhibit Hall

o   This post-hoc analysis of data from the Phase III HARBOR study identified the time of peak vision gains of wet AMD patients treated with ranibizumab either as needed (PRN) or monthly.

o   Results showed most patients reached peak vision after more than six months of treatment regardless of PRN or monthly dosing, suggesting that consistent treatment may be important for long-term benefit.

  • “Baseline Characteristics Associated With Good Visual Acuity Outcomes In Myopic Choroidal Neovascularization: Results From The RADIANCE Trial” – Presented by Carolyn Pan, M.D.

Sunday, April 29, 3:30pm – 3:45 HST; Paper Session: Macular Diseases Excluding AMD; Room 316C

o   This post-hoc analysis of the Phase III RADIANCE study identified several baseline demographic and ocular characteristics that were predictive of good visual outcomes (defined as 20/40 or better vision) in response to ranibizumab treatment in patients with myopic CNV.

o   The results also showed that prompt treatment with ranibizumab increased the chances of good visual outcomes.

  • “Long-Term Outcomes In Ranibizumab-Treated East Asian Patients With Myopic Choroidal Neovascularization In The 36-Month Post-RADIANCE Study Period” – Presented by Mark Weiland, M.D.

Sunday, April 29, 3:45pm – 4:00 HST; Paper Session: Macular Diseases Excluding AMD; Room 316C

o   This retrospective study assessed the long-term safety and efficacy of ranibizumab for myopic CNV in East Asian patients from the Phase III RADIANCE study over an additional 36 months following trial completion.

o   The study found that East Asian patients treated with ranibizumab maintained the significant vision gains they achieved at month 12 over an additional 3-year period, with the majority (82.9 percent) requiring no additional treatment.

  • “Baseline Factors Associated With ≥ 2-Step Diabetic Retinopathy (DR) Severity Improvement With Ranibizumab (RBZ)” – Presented by Dilsher Dhoot, M.D., Poster: A0210

Tuesday, May 1, 3:30pm – 5:15pm HST; Poster Session: Diabetic Macular Edema Anti-VEGF; Exhibit Hall

o   This analysis of data from the Phase 3 RISE and RIDE studies examined which baseline characteristics were associated with ≥ 2-step DR severity improvements.

o   Factors that were found to be significantly associated with improvement in patients receiving ranibizumab included younger age, shorter duration of diabetes and less severe disease at baseline.

 

Related Content